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Background: Identification of specific risk groups for recurrence after surgery for isolated
colorectal liver metastases (CRLM) remains challenging due to the heterogeneity of the dis-
ease. Classical clinicopathologic parameters have limited prognostic value. The aim of this
study was to identify a gene expression signature measured in CRLM discriminating early
from late recurrence after partial hepatectomy.
Methods: CRLM from two patient groups were collected: I) with recurrent disease 12
months after surgery (N ¼ 33), and II) without recurrences and disease free for 36 months
(N ¼ 30). The patients were clinically homogeneous; all had a low clinical risk score (0e2)
and did not receive (neo-) adjuvant chemotherapy. Total RNA was hybridised to Illumina
arrays, and processed for analysis. A leave-one-out cross validation (LOOCV) analysis
was performed to identify a prognostic gene expression signature.
Results: LOOCV yielded an 11-gene profile with prognostic value in relation to recurrent
disease 12 months after partial hepatectomy. This signature had a sensitivity of 81.8%,
with a specificity of 66.7% for predicting recurrences (12 months) versus no recurrences
for at least 36 months after surgery (X2 P < 0.0001).
Conclusion: The current study yielded an 11-gene signature at mRNA level in CRLM
discriminating early from late or no relapse after partial hepatectomy.
ª 2016 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.gical Oncology, Erasmus MC Cancer Institute, P.O. Box 5201, 3008 AE Rotterdam, The
c.nl (E.P. van der Stok).
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MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 5 4 2e1 5 5 0 15431. Introduction 2. MethodsColorectal cancer is one of the most commonly diag-
nosed cancers worldwide (Torre et al., 2015). Approxi-
mately 15e25% of patients with colorectal cancer (CRC)
present with synchronous liver metastases and another
20% have a metachronous disease development (van der
Pool et al., 2012). For patients presenting with isolated liver
metastases, partial hepatectomy is the only potentially
curative treatment option. Reported 5-year survival rates
are 40e60% (Dols et al., 2009; Rees et al., 2008; Primrose,
2010). A substantial number of patients develop recurrent
disease after liver surgery, underlining the need for prog-
nostic biomarkers (D’Angelica et al., 2011; Butte et al.,
2015; de Jong et al., 2009). Such prognostic biomarkers
may allow a more personalised treatment strategy. In
recent years, several clinicopathological prognostic vari-
ables in patients with isolated colorectal liver metastases
(CRLM) have been identified predicting the risk of relapse
after a metastasectomy (Matias et al., 2015). These vari-
ables have been integrated in various clinical risk scores
(CRS) (Matias et al., 2015; Fong et al., 1999; Konopke et al.,
2009; Nagashima et al., 2004; Nordlinger et al., 1996). The
CRS according to Fong et al. is the most widely used and
validated score, able to distinguish between high risk and
low risk patients in terms of survival outcomes (Fong
et al., 1999). This score is composed of 5 prognostic vari-
ables: positive lymph node status of the primary tumour,
diagnosis of liver metastases within 12 months after resec-
tion of primary tumour, serum CEA 200 ng/ml, >1 liver
metastases, a metastasis of >5 cm diameter. Each variable
accounts for 1 point. Patients with 0e2 points are categor-
ised as low risk, patients with 3e5 points as high risk. Still,
outcomes after surgery remain heterogeneous: low risk pa-
tients may develop early recurrences e approximately 50%
of patients with a low CRS develop metastases within 12
months after surgery e while high risk patients may
remain disease free (Poston, 2008; Poston et al., 2008).
Unravelling the biological properties characterising tu-
mours may be pivotal to designing individualised thera-
pies, based on biological predictors of outcome rather
than or in addition to clinical predictors. Various groups
have established molecular subtypes in primary cancers
with distinct biology, predictive and prognostic value
(Guinney et al., 2015;Paik et al., 2004; Hoshida et al., 2008;
Albain et al., 2010; Budinska et al., 2013; Sadanandam
et al., 2013). Biological markers may improve patient selec-
tion for (neo-) adjuvant therapies in addition to surgical
management or intensive surveillance schemes.
The ability to analyse tumours at DNA-, RNA-, and protein-
level promises to revolutionize our understanding of the ma-
lignant disease process, and hopefully this will herald new
(superior) biomarkers. The aim of the current study was to
identify a prognostic gene signature at mRNA level in patients
with a low CRS, effective in identifying patients at high risk of
early recurrence after surgery for CRLM.2.1. Patient and treatment
Erasmus MC Cancer Institute is a tertiary referral centre for
liver surgery. In the current retrospective study, patient char-
acteristics were collected from a prospectively maintained
database. All patients undergoing resection for CRLM are pro-
spectively entered into an institutional database. This data-
base includes standard clinicopathological variables.
Patients selected for the current study had a low risk profile
(Fong’s clinical risk score 0e2 (Fong et al., 1999)) and did not
receive treatment with (neo-) adjuvant chemotherapy for
the resectable CRLM in line with the Dutch guidelines that
do not support routine administration of chemotherapy/bio-
logicals in the case of primary resectable colorectal liver-
only metastases. Patients were further selected according to
the following criteria: I) patients with recurrent disease within
12 months after hepatectomy, and II) patients without recur-
rent disease and a disease free survival of at least 36 months
after hepatectomy. Thus, “two extremes” were selected in
terms of recurrent disease. All resections were performed be-
tween 2000 and 2009. Hepatic parenchymal resectionwas per-
formed with an ultrasonic surgical aspirator and a monopolar
coagulator. R0-resections were defined by the absence of
microscopic tumour invasion of the resection margins, and
R1-resections were defined by the presence or microscopic
tumour invasion of the resection margins (Ayez et al., 2012).
During follow-up, patients visited the outpatient clinic
every 4 months in the first 2 years after CRLM resection for
clinical examination and CEA-determination. Thereafter, pa-
tients visited the outpatient clinic every 6 months and were
discharged from follow up after 5 years. Abdominal imaging
(CT of thorax and abdomen) was performed twice a year dur-
ing the first 3 years and thereafter annually. If disease
recurred, a decision on whether to initiate chemotherapy
treatment or to perform local therapywasmade by amultidis-
ciplinary team. Disease free survival (DFS) was defined as the
interval inmonths between resection of CRLM and recurrence.
2.2. Tissue collection and assessment
After resection of CRLM, tumour tissue is standardly fixed on
formalin and embedded in paraffin in the department of pa-
thology according to standard protocols, and stored. For the
current study, tumour samples (N ¼ 80) of CRLM were
retrieved from the selected patient groups. In the case a pa-
tient had more than one metastasis, there were no additional
selection criteria in terms of which tumour to analyse. The
formalin fixed, paraffin embedded (FFPE) samples were evalu-
ated by a pathologist for colon tumour cell content: only spec-
imens with at least 30% tumour cells in the tissue block were
included (N ¼ 63). The final study population consisted of 33
samples for group I with disease recurrence within 12 months
and 30 samples for group II without disease recurrence and a
DFS of 36 months.
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dedicated pathologist and at least one additional observer in
all resected CRLM in Erasmus MC Cancer Institute
(Vermeulen et al., 2001; Van den Eynden et al., 2013). Three
tumour growth patterns have been reported in literature,
with a distinct growing pattern (Vermeulen et al., 2001; Van
den Eynden et al., 2013). These patterns consist of a pushing
type, a replacing type and a desmoplastic type. Briefly, in the
pushing type the metastasis has a displacing interaction
with the normal liver parenchyma, and is separated from
normal cells by a thin layer of reticulin fibres. The replacing
type infiltrates the normal liver parenchyma. The desmoplas-
tic type has a band of desmoplastic tissue that separates
tumour cells from the liver parenchyma.
On a patient level, the growth patterns were classified by
two methods for analysis in relation to outcomes. First,
when a pattern was expressed in >75% of the CRLM the pa-
tient was classified as such. If no pattern was expressed in
>75%, the growth pattern was classified as a “mixed type”.
Second, based on prognostic evidence reported in the litera-
ture, if any percentage of the pattern was a replacement
type, the patient was classified as such (Van den Eynden
et al., 2012; Okano et al., 2000; Lunevicius et al., 2001; Eefsen
et al., 2015). Tumour differentiation and inflammation at the
leading edge of the tumour were also objectified, for the cur-
rent study specifically.
2.3. RNA extraction and purification
Depending on the size of the FFPE samples, total RNA was
extracted from 3 to 6  20 mm sections. Following paraffin
removal with xylene the high-pure RNA paraffin kit was
used according the supplier’s instructions (Roche, Mannheim,
Germany). Following isolation, RNA was stored in RNase/
DNase-free water at 80 C. Quality control was performed
as previously described (Mustafa et al., 2015).
2.4. Gene expression profiles
Illumina Whole Genome-cDNA-mediated Annealing, Selec-
tion, Extension and Ligation (WG-DASL) V4 assay is an
array-based method for expression profiling of partially
degraded RNA molecules such as those isolated from
Formalin-Fixed Paraffin-Embedded samples. In the
HumanHT-12 v4 BeadChip assay 29,285 annotated transcripts
corresponding to 27,253 coding transcripts with well-
established annotations are measured. The WG-DASL assay
was performed according to the manufacturer’s instructions.
In summary, 1000 ng total RNA was used from the 63 FFPE
samples. 500 ng of total RNA from a pool of fresh frozen
tumour RNA samples (I-scan control) was included in each in-
dividual hybridisation experiment of 11e23 samples to eval-
uate possible inter-assay differences (Supplementary 1).
Total RNA was converted to cDNA using biotinylated oligo-
dT18 and random nonamer primers. The biotinylated cDNA
was annealed to the DASL Assay Pool (DAP) probe groups,
which contain oligonucleotides specifically designed to inter-
rogate each target sequence of the transcript. The DAP
was annealed to targeted cDNA during a 16 h tempera-
ture gradient (70e37 C) incubation. Hybridisation of theseoligonucleotides to the targeted cDNA site, followed by enzy-
matic extension and ligation was used to create a Polymerase
Chain Reaction (PCR) template that was amplifiedwith a set of
universal PCR primers (Fan et al., 2004). Cy3-coupled primers
were used to facilitate the precipitation of the single stranded
labelled products, which were hybridised to the whole
genome HumanHT-12 v4 BeadChips containing 12 identical
microarrays each. The microarrays were scanned using a
confocal type imaging system with Cy3 (532 nm) laser illumi-
nation Illumina I-scan reader (N0262). Fluorescent intensities
were read and images were extracted using software version
1.8.13.5. Each sequence type is represented by an average of
30 beads on the array.
Eight hybridisations did not meet our criteria of an average
intensity signal of at least 500 prior to background correction
and normalisation and were re-measured at an input of
2000 ng total RNA.
2.5. Data analysis
Scanned data were uploaded into GenomeStudio software
version 2011.1 via the Whole Genome DASL gene expression
module for further analysis. The average signal, detection P-
value, Bead standard error and average beads were used to
quantile normalise the data in the statistical language R
(www.r-project.org) using the “lumi” package (Du et al.,
2008). The expression raw data are available at the Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/entry
nr.: GSE81423).
2.6. Statistics
A leave-one-out cross validation (LOOCV) was performed us-
ing Biometric Research Branch ArrayTools (BRB-ArrayTools,
http://linus.nci.nih.gov/BRB-ArrayTools.html), starting with
the top 25% most variable genes (N ¼ 7101) in all samples as
input. Samples were classified in two classes: recurrences
12 months (class 1) or no recurrences and a disease free sur-
vival 36 months (class 2). In each round of the LOOCV, genes
with a univariate P-value <0.001 were selected to differentiate
between class 1 and class 2 (patients with and without recur-
rent disease). The linear prediction rule was defined by the in-
ner sum of the weights (Wi) and expression (Xi) of these
significant genes. In the prediction model, a sample was clas-
sified to class 2 if the sum was greater than the established
threshold (
P
iWiXi > threshold). From the available prediction
algorithms, the “Support Vector Machine” (SVM) proved the
most accurate classifier (75% correct classification,
Supplementary 2), resulting in an 11-gene signature (Table
3). Through this algorithm, each patient could be classified
as “high risk” or “low risk” on basis of the identified expression
profile (molecular risk).
Descriptive values are expressed as median (interquartile
range (IQR)). Variables were compared by means of Chi-
square analysis or Fischer’s exact test (depending on the sam-
ple size) or with the independent Student’s t test or Man-
neWhitney U test when appropriate. The SPSS statistical
package (version 21.0, Chicago, IL, USA) was used for statisti-
cal analysis; a two-sided P-value of 0.05 was considered sta-
tistically significant.
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Of all patients, an informed consent was available, to use re-
sidual tissue for research purposes. The data and tissue used
in the current study was employed in an anonymous fashion.
As prescribed by national regulations, the current study was
not subject to the “Medical Research Involving Human Sub-
jects Act”.3. Results
3.1. Patients
Clinicopathological features of both patient groups (with re-
currences 12 months and without recurrences and a DFS
36 months) are outlined in Table 1. The groups were homo-
geneous in terms of clinicopathological characteristics, as ex-
pected since all patients were selected to have a low CRS
according to Fong (Matias et al., 2015). Therewas no difference
in tumour differentiation, histological growth pattern and
inflammation (at the leading edge of the tumour). The respec-
tive molecular risk groups did not differ on basis of the
assessed biological (pathological) characteristics.
3.2. Genes associated with early recurrence
Through a LOOCV analysis, an 11-gene profile was con-
structed capable of discriminating patients at high-from low
risk of recurrence (Table 3 and Supplementary 3). Clinicopath-
ological features of patients by the identified molecular risk
groups (low- and high-risk) are depicted in Table 2. These
groups differed on basis of location of primary tumour and,
inherently, the administration of neo-adjuvant radiotherapy
for primary CRC. Of the 37 patients with at high molecular
risk, 27 developed recurrent disease within 12 months. This
yielded a sensitivity of the signature of 81.8%, with a speci-
ficity of 66.7% (X2 P < 0.0001, Table 4a). From the group of pa-
tients with recurrences within 12 months, the subgroup of
patients with hepatic recurrences was identified (N ¼ 17). All
patients with hepatic recurrences were at high molecular
risk based on the 11-gene signature, resulting in a 100% sensi-
tivity and 56% specificity for hepatic recurrences specifically
(X2 P < 0.0001, Table 4b).
In the KEGG Pathway Database (http://www.genome.jp/
kegg/pathway.html) and Gene Ontology Consortium database
(http://geneontology.org) the respective genes were searched
and pathways in which they are known to be involved are
depicted in Supplementary 4 (KEGG) and Supplementary 5
(Gene Ontology). Two genes, CLRN3 and KIAA0219, have not
been described and not been registered in both databases.4. Discussion
The clinical and biological diversity of CRLMurges the need for
prognostic biomarkers and tailor-made treatment strategies
(Poston et al., 2008). Despite improvement of therapies for
liver-only stage IV CRC resulting in improved survival rates,
knowledge on treatment response and risks of relapse orprogression is still scarce. A substantial number of patients
develop recurrent disease following resection of CRLM, under-
lining the need for prognostic factors (D’Angelica et al., 2011;
Butte et al., 2015; de Jong et al., 2009). More insights into biolog-
ical tumour behaviour may result in better understanding of
treatment failure and may yield biomarkers for risks of
relapse or prediction of response to therapy. This could
improve identification of patients who will or will not benefit
from tailored treatment strategies, e.g. more intensified (neo-)
adjuvant treatments for those with a high risk for relapse and
potentially less intensified approaches for those with a low
risk profile. Currently, prognostication and prediction in
resectable CRLM is solely based on clinical parameters, with
sub-optimal performance. As an exception, KRAS/BRAFmuta-
tion statusmay impact response to treatment and outcome in
CRLM as in primary colorectal cancer (Passiglia et al., 2016;
Karagkounis et al., 2013; Lin et al., 2014; Loes et al., 2016;
Margonis et al., 2015; Vauthey et al., 2013). Nevertheless,
both clinical and the latter mutational status fails to impact
clinical management of CRLM (Zakaria et al., 2007).
In the present study, mRNA expression profiles in CRLM
were objectified in low risk patients who underwent hepatec-
tomy with curative intent, without (neo-) adjuvant chemo-
therapy. All patients were homogeneous in terms of clinical
risk, as defined by current standards (Matias et al., 2015).
Within this homogeneous group with respect to clinical risk,
we were still able to select two opposite ends of the clinical
spectrum: patients with recurrences within 12 months after
surgery and patients without recurrences for at least 36
months post-surgery. Analysis of differential gene expression
of CRLM of these 2 adverse patient groups resulted in the iden-
tification of an 11-gene expression profile, able to discriminate
between patientswith early versus late or no recurrences after
partial hepatectomy.
The fact that we were still able to identify two extremes (in
terms of time to recurrence) in a clinically homogeneous
group confirms the shortcomings of classic clinical risk
scoring. The selection of these specific groups provided the
opportunity to findmolecular differences involved in outcome
in a cohort where clinical parameters are incapable to do so.
As all patients were chemo naive, true prognostic impact
(tumour biology) could be researched. Chemo-naivety ruled
out potential influences of the systemic regimens on the
RNA expression in the tumour samples. Comparable studies
lack true focus on prognostics, since the majority of these pa-
tients underwent pre- or postoperative systemic treatment
(Ito et al., 2013; Snoeren et al., 2012; Balachandran et al.,
2016). The current chemo na€ıve patient cohort is unique,
and the molecular risk profile identified in the current study
therefore promising.
There is a strong potential for gene expression based-
biomarkers such as the one identified in the current study.
The 11-gene signature may serve as a novel blueprint for indi-
vidualised therapies; either in combination with or without
the classic clinical risk scores. Identification of patients for
neo-adjuvant (preoperative) therapy is certainly possible since
prognostic gene expression profiles may be detected in liquid
biopsies before surgery (Mostert et al., 2013, 2015). Currently
the clinical risk scores do not impact clinical management,
although some retrospective reports have suggested they
Table 1 e Clinicopathological characteristics of patients by recurrence.
DFS 12
Months (N ¼ 33)
DFS 36 þ No recurrence
Months (N ¼ 30)
All patients (N ¼ 63)
Value %/IQR Value %/IQR P-value Value %/IQR
Male 19 58% 18 60% 0.845a 37 59%
Age Median 67 58e71 63.5 58-72 0.895b 65 58e72
Primary tumour
Location (right sided) 6 18% 4 13% 0.599a 10 16%
Rectal cancer 17 52% 12 40% 0.360a 29 46%
T stage 3/4 25 76% 23 77% 0.933a 48 76%
Positive lymph node (pNþ) 17 52% 14 47% 0.701a 31 49%
Adjuvant CTx 8 24% 6 20% 0.686a 14 22%
Neo-adjuvant RTx 10 32% 6 20% 0.277a 16 26%
Liver metastases
CEA > 200 2 6% 0 0% 0.164a 2 3%
Synchronous DFI < 12 11 33% 9 30% 0.777a 20 32%
Diameter > 5 (cm) 6 18% 3 10% 0.354a 9 14%
Number of mets > 1 7 21% 6 20% 0.905a 13 21%
Bilobar 6 18% 4 13% 0.599a 10 16%
R1 resection 5 15% 1 3% 0.110a 6 10%
Growth pattern 1 Replacement 23 70% 16 53% 0.284a 39 62%
Desmoplastic 3 9% 7 23% 10 16%
Pushing 1 3% 0 0% 1 2%
Mixed 6 18% 7 23% 13 21%
Growth pattern 2 Replacement (any) 28 85% 22 73% 0.259a 50 79%
Differentiation Good 4 13% 2 7% 0.657a 6 10%
Moderate/good 3 10% 6 21% 9 15%
Moderate 6 19% 5 18% 11 19%
Poor/moderate 11 36% 11 39% 22 37%
Poor 7 23% 4 14% 11 19%
Inflammation Increased 5 16% 5 18% 0.321a 10 17%
Moderate/increased 3 10% 8 29% 11 19%
Moderate 10 32% 8 29% 18 31%
Decreased/moderate 6 19% 2 7% 8 14%
Decreased 7 23% 5 18% 12 20%
DFS ¼ Disease Free Survival; pNþ ¼ Pathological Node Positivity; CTx ¼ Chemotherapy; RTx ¼ Radiotherapy; CEA¼Carcinoembryonic Antigen;
R1 ¼ Microscopic Irradical.
a Pearson X2.
b ManneWhitney U test.
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prospectively investigated at present in the CHARISMA trial
(Ayez et al., 2015b)). Theremay be a synergistic effect between
the clinical risk score and the molecular score of the current
study. As all patients developing liver recurrences in the cur-
rent study were at high molecular risk, the 11-gene signature
may also play a role in identifying patients that benefit from
regional chemotherapy specifically (e.g. hepatic arterial infu-
sion pump (Kemeny et al., 1999)). Therefore, after thorough
validation, the current biomarkermay be effective in selecting
patient groups for various treatment strategies.
Therewas no clear link between themRNA expression pro-
files and other previously identified pathological features in
CRLM, such as the tumour growth patterns. As stated earlier,
three types of CRLM growth patterns can be observed: a push-
ing type, a replacing type and a desmoplastic type (Vermeulen
et al., 2001; Van den Eynden et al., 2013). The clinical impact of
these growth patterns is still under investigation as their
pathological presence is widely recognised. The molecular
risk groups of the current study may be associated with a cor-
responding distinctive phenotype, possibly in the form of any
of the established growth patterns. If such apparent tumourphenotypes exist, one could hypothesise that obvious differ-
ences may be recognisable at molecular level accordingly. In
the current study, there was a trend towards an association
between the high molecular risk group and the replacing
growth pattern. A replacing growth pattern has repeatedly
been associatedwithworse outcomes as compared to the des-
moplastic growth pattern (Eefsen et al., 2015; Nielsen et al.,
2014; Pinheiro et al., 2014). In the current study the association
is argumentative. A possible explanation for the lack of signif-
icance may be that these growth patterns are a specific char-
acteristic of the leading edge of tumours. The gene expression
data from the tumour samples in the current study are not
exclusively retrieved from tumour tissue present in the lead-
ing edge. Currently, gene expression profiles for each of the
growth patterns are assessed in an on-going study through
laser macro-dissection of representative parts of the tumour.
Some of the functional annotations of the 11 genes in the
signature provided insight into underlying biological mecha-
nisms involved in recurrence, yet no evident common path-
ways could be discerned (see Supplementaries 4 and 5).
JARID1A, one of the 11 genes, is part of the “KDM5 family” of
histone demethylases removing tri- and di-methylation
Table 2 e Clinicopathological characteristics of patients by molecular risk.
High risk (N ¼ 37) Low risk (N ¼ 26) All patients (N ¼ 63)
Value %/IQR Value %/IQR P-value Value %/IQR
Male 21 57% 16 62% 0.704a 37 59%
Age Median 64 57e70 68 60e72 0.718b 65 58e72
Primary tumour
Location (right sided) 4 11% 6 23% 0.190a 10 16%
Rectal cancer 21 57% 8 31% 0.042a 29 46%
T stage 3/4 30 81% 18 69% 0.277a 48 76%
Positive lymph node (pNþ) 20 54% 11 42% 0.359a 31 49%
Adjuvant CTx 7 19% 7 27% 0.452a 14 22%
Neo-adjuvant RTx 13 37% 3 12% 0.025a 16 26%
Liver metastases
CEA > 200 2 6% 0 0% 0.222a 2 3%
Synchronous DFI < 12 12 32% 8 31% 0.889a 20 32%
Diameter > 5 (cm) 7 19% 2 8% 0.210a 9 14%
Number of mets > 1 7 19% 6 23% 0.688a 13 21%
Bilobar 5 14% 5 19% 0.541a 10 16%
R1 resection 5 14% 1 4% 0.198a 6 10%
Growth pattern 1 Replacement 27 73% 12 46% 0.106a 39 62%
Desmoplastic 4 11% 6 23% 10 16%
Pushing 1 3% 0 0% 1 2%
Mixed 8 31% 5 14% 13 21%
Growth pattern 2 Replacement (any) 29 78% 21 81% 0.817a 50 79%
Differentiation Good 4 11% 2 9% 0.975a 6 10%
Moderate/good 5 14% 4 17% 9 15%
Moderate 6 17% 5 22% 11 19%
Poor/moderate 14 39% 8 35% 22 37%
Poor 7 19% 4 17% 11 19%
Inflammation Increased 5 14% 5 22% 0.513a 10 17%
Moderate/increased 5 14% 6 26% 11 19%
Moderate 11 31% 7 30% 18 31%
Decreased/moderate 6 17% 2 9% 8 14%
Decreased 9 25% 3 13% 12 20%
DFS ¼ Disease Free Survival; pNþ ¼ Pathological Node Positivity; CTx ¼ Chemotherapy; RTx ¼ Radiotherapy; CEA ¼ Carcinoembryonic Antigen;
R1 ¼ Microscopic Irradical.
a Pearson X2.
b ManneWhitney U test.
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actively transcribed genes. We find JARID1A upregulated in
patients with early recurrences in the current study which is
in line with growing evidence for a causal role of this marker
in relation to cancer progression (Rasmussen and Staller,Table 3 e The identified 11-gene signature.
Nr. Parametric P-value Fold-change Unique ID Name
1 5.53e-05 0.55 ILMN_1786920 JARID1A
2 0.0003634 0.51 ILMN_1698404 ERN1
3 0.0004586 0.47 ILMN_1683082 RPUSD1
4 0.0004769 0.59 ILMN_2067408 CLRN3
5 0.0009447 0.53 ILMN_1668374 ITGB5
6 0.0007405 2.07 ILMN_1678061 CASS4
7 0.0006431 1.79 ILMN_1684183 RAD9A
8 0.0004545 1.8 ILMN_3238676 ULBP2
9 0.0002883 1.98 ILMN_2381758 G3BP2
10 0.0002758 2.03 ILMN_1783636 COX6A1
11 0.0002593 1.87 ILMN_1656042 KIAA0319
P-value, Relative fold change (DFS 12 months vs. no recurrence
and DFS 36 months), ID, Names (annotations) of genes.2014). ERN1 (endoplasmic reticulum to nucleus signalling 1)
is an important endoplasmic reticulum (ER) stress sensor.
ERN1 signalling is a pro-angiogenic mechanism (Rahbari
et al., 2014) and since we found ERN1 increased in patients
with early recurrences, angiogenesis may be a contributing
factor. Natural killer group 2, member D ligand ULBP2 andTable 4ae Prognostic impact of the molecular risk profile for all site
recurrences.
True recurrence Molecular risk
Low High Total
No 20 10 30
Yes 6 27 33
Total 26 37 63
Sensitivity 81.8%
Specificity 66.7%
PPV 73%
NPV 76.9%
Pearson X2: P < 0.0001.
PPV¼Positive Predictive Value; NPV¼Negative Predictive Value.
Table 4b e Prognostic impact of the molecular risk profile for
hepatic recurrences.
True recurrence Molecular risk
Low High Total
No 26 20 46
Yes 0 17 17
Total 26 37 63
Sensitivity 100%
Specificity 56%
PPV 46%
NPV 100%
Pearson X2: P < 0.0001.
PPV¼Positive Predictive Value; NPV¼Negative Predictive Value.
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induced proteins contributing to progression. ULBP2, whose
expression is low in patients having an early recurrence and
whose receptor is on the surface of natural killer (NK) cells
and specific T-cells, implies immune modulation (Ayez et al.,
2015b) in recurrence. G3BP2 is known to affectmatrix stiffness
as does RPUSD1 (RNA pseudouridylate synthase domain con-
taining 1) by controlling lateral growth of collagen II fibrils.
G3BP2 and RPUSD1, with decreased and increased expression
in the current study respectively, suggest that extracellular
remodelling may affect the occurrence of recurrences as
well. Potentially connected to the latter we find integrin sub-
unit beta 5 (ITGB5), which is overexpressed in higher stages
of CRC (Kemeny et al., 1999) and which modulates adhesion
phenomena, and CASS4 the less studied signalling scaffold
of the CAS (Crk-associated substrate) family which affects
motility. Expression of these genes was elevated (ITGB5) and
decreased (CASS4) in patientswith early recurrence in the cur-
rent study implying a role formigration, invasion and possibly
progenitor cell function (Nielsen et al., 2014) and inhibition of
apoptosis in cancer recurrence as well. The barely studied
KIAA0319L and transmembrane protein clarin 3 (CLRN3) as
well as COX6A1, which is involved in oxidative phosphoryla-
tion, affect recurrence rate but for now we cannot connect
these proteinsmechanistically to disease progression. Finally,
the RAD9A checkpoint protein is required for proper localiza-
tion of topoisomerase II-binding protein 1 (TopBP1) regulating
cell cycle checkpoints, DNA repair, telomere stability and
apoptosis (Greer Card et al., 2010; Broustas and Lieberman,
2012; Lieberman et al., 2011) thereby preserving genomic
integrity in all types of DNA aberrations (Greer Card et al.,
2010; Broustas and Lieberman, 2012; Lieberman et al., 2011).
In the current study, RAD9A was relatively downregulated in
patients with early recurrences suggesting loss of genomic
integrity is another contributing factor to recurrence
(Broustas and Lieberman, 2012). Overall, we can conclude
that recurrence of metastatic colorectal cancer in the liver is
influenced by multiple complementary factors.
Limitations of the current study are its retrospective na-
ture, the selection bias in terms of DFS and a relatively small
sample size. Based on the current study, it is challenging to
provide advice regarding treatment management for the pa-
tient group 36 > DFS > 12. The present molecular markerprofile therefore needs extensive validation in a larger inde-
pendent cohort. This cohort should consist of patients repre-
senting the complete (continuous) spectrum in relation to
recurrent disease, and possibly (but not necessarily) with
both high- and low-clinical risk scores. The current setting
with two extremes in terms of recurrences was chosen as a
first step in establishing a prognostic signature. If any rele-
vant expression profiles exist in relation to recurrent disease,
they are most likely to be identified within these extremes.
KRAS and BRAF status would have been informative in terms
of assessment of baseline risk for relapse. It is a timely topic
of interest in CRLM. These molecular entities were not avail-
able in the current cohort. Ideally, in a validation study for
the current molecular biomarker, all known prognostic mo-
lecular factors should be assessed (including other estab-
lished signatures) such that all respective molecular
markers can be put into context (Passiglia et al., 2016;
Karagkounis et al., 2013; Lin et al., 2014; Loes et al., 2016;
Margonis et al., 2015; Vauthey et al., 2013; Ito et al., 2013;
Snoeren et al., 2012; Balachandran et al., 2016). A general
point of discussion related to this type of translational
research is the impact of inter- and intra-tumour heterogene-
ity on the reproducibility of results. Multiple studies show
that even within single tumours heterogeneity exists
(Marusyk et al., 2012; Tabassum and Polyak, 2015). Despite
any consensus on what lesion to analyse (e.g.: the largest)
or what area within a tumour (e.g.: leading edge or core), het-
erogeneity will affect the generated results. Interestingly,
these features of heterogeneity are known to have prognostic
associations by itself in resected colorectal liver metastases
(Sveen et al., 2016). Future studies should possibly also
address spatial and temporal tumour heterogeneity, in addi-
tion to identification of a new biomarker.5. Conclusion
In summary, in the current study a prognostic signature was
constructed with the mRNA expression profiles of tumour
tissue from resected CRLM. The signature consists of 11
genes of which the expression-patterns were able to
discriminate between patients with early recurrences (12
months) versus no recurrences (36 months) after partial
hepatectomy. This biomarker requires validation in a larger
cohort representative of the complete clinical spectrum in
terms of relapse and treated without (neo-) adjuvant ther-
apy, including any other established prognostic molecular
markers.Conflict of interest
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